DCVax^®-Brain and DC vaccines in the treatment of GBM

Bibliography

• DeAngelis LM. Medical progress: brain tumors. N Engl J Med2001;344:114-23
   PubMed Web of Science ®Google Scholar
• Davis FG, Kupelian V, Freels S, et al. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-oncol2001;3:152-8
   PubMed Web of Science ®Google Scholar
• Curran WJJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst1993;85:690-1
   PubMed Web of Science ®Google Scholar
• Fine HA, Dear KBG, Loeffler JS. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer1993;71:2585-97
   PubMed Web of Science ®Google Scholar
• Reavey-Cantwell JF, Haroun RI, Zahurak M, et al. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol2001;55:195-204
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME. Recent developments in the management of malignant glioma. J Clin Oncol2003;1091-9118:779-88
   Google Scholar
• Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg1993;78:762-6
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg2001;95:190-8
   PubMed Web of Science ®Google Scholar
• Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol2002;20:1375-82
   PubMed Web of Science ®Google Scholar
• Dandy WE. Removal of the right cerebral hemishpere for certain tumors with hemiplegia. J Am Med Assoc1928;90:823-5
   Google Scholar
• Burger PC. Pathologic anatomy and CT correlations in the glioblastoma multiforme. Appl Neurophysiol1983;46:180-7
   PubMedGoogle Scholar
• Feun LG, Wallace S, Yung WK, et al. Phase-I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors. Cancer Drug Deliv1984;1:239-45
   PubMedGoogle Scholar
• Kapp JP, Sanford RA. Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of risk factors. Neurosurgery1986;19:779-83
   PubMed Web of Science ®Google Scholar
• Oldfield EH, Clark WC, Dedrick RL, et al. Reduced systemic drug exposure by combining intraarterial cis-diamminedichloroplatinum(II) with hemodialysis of regional venous drainage. Cancer Res1987;47:1962-7
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Tamiya T, Adachi Y, et al. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther2000;7:74-82
   PubMed Web of Science ®Google Scholar
• Diete S, Treuheit T, Dietzmann K, et al. Sex differences in length of survival with malignant astrocytoma, but not with glioblastoma. J Neurooncol2001;53:47-9
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today1997;18:175-82
   PubMedGoogle Scholar
• Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med1990;172:631-40
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity. Nat Med1995;1:1297-302
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med1996;183:87-97
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci USA1996;93:10399-404
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med1997;3:558-61
   PubMed Web of Science ®Google Scholar
• Wang J, Saffold S, Cao X, et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol1998;161:5516-24
   PubMed Web of Science ®Google Scholar
• Okada H, Tahara H, Shurin MR, et al. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer1998;78:196-201
   PubMed Web of Science ®Google Scholar
• Matsui S, Ahlers JD, Vortmeyer AO, et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol1999;163:184-93
   PubMed Web of Science ®Google Scholar
• Walker PR, Calzascia T, Schnuriger V, et al. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J Immunol2000;165:3128-35
   PubMed Web of Science ®Google Scholar
• Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med1994;180:83-93
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med1996;2:52-8
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med1998;4:328-32
   PubMed Web of Science ®Google Scholar
• Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate1996;29:371-80
   PubMed Web of Science ®Google Scholar
• Murphy GP, Tjoa BA, Simmons SJ, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate1999;38:73-8
   PubMed Web of Science ®Google Scholar
• Murphy GP, Tjoa BA, Simmons SJ, et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate1999;39:54-9
   PubMed Web of Science ®Google Scholar
• Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol2001;166:4254-9
   PubMed Web of Science ®Google Scholar
• Holtl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol1999;161:777-82
   PubMed Web of Science ®Google Scholar
• Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med2000;6:332-6
   PubMed Web of Science ®Google Scholar
• Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA2001;98:8809-14
   PubMed Web of Science ®Google Scholar
• Morse MA, Nair S, Fernandez-Casal M, et al. Peroperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol2000;18:3883-93
   PubMed Web of Science ®Google Scholar
• Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pused dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res2001;61:842-7
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother2001;50:337-44
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer2003;89:1172-9
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T cells in patients with malignant glioma. Cancer Res2004;64:4973-9
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med1998;4:321-7
   PubMed Web of Science ®Google Scholar
• Lee KH, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol1999;163:6292-300
   PubMed Web of Science ®Google Scholar
• Bodey B, Bodey BJ, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res2000;20:2665-76
   PubMed Web of Science ®Google Scholar
• Panelli MC, Wunderlich J, Jeffries J, et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother2000;23:487-98
   PubMed Web of Science ®Google Scholar
• Liénard Rimoldi D, Marchand M, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immunol Immunother2004;4:4
   Google Scholar
• Walker EB, Haley D, Miller W, et al. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res2004;10:668-80
   PubMed Web of Science ®Google Scholar
• Marchand M, Brichard V, van Baren N, Coulie PG. Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther2001;1:497-510
   PubMed Web of Science ®Google Scholar
• Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother2004;53:249-55
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res2008;68:5955-64
   PubMed Web of Science ®Google Scholar
• Bigner DD, Pitts OM, Wikstrand CJ. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg1981;55:32-42
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Bigner DD, et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM [abstract 2011]. J Clin Oncol2008;26:(Suppl):92s
   Google Scholar
• Matsuda M, Petersson M, Lenkei R, et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer1995;61:765-72
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Cirignano B, Chamian F, et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer2004;109:893-9
   PubMed Web of Science ®Google Scholar
• Waziri A, Killory B, Ogden ATR, et al. Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol2008;180:7673-80
   PubMed Web of Science ®Google Scholar
• Siesjo P, Visse E, Sjogren HO. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol1996;19:334-45
   PubMed Web of Science ®Google Scholar
• Toes REM, van der Voort EIH, Schoenberger SP, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation of dendritic cells. J Immunol1998;160:4449-56
   PubMed Web of Science ®Google Scholar
• Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg1999;90:1115-24
   PubMed Web of Science ®Google Scholar
• Ni HT, Spellman SR, Jean WC, et al. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol2001;51:1-9
   PubMed Web of Science ®Google Scholar
• Trakatelli M, Toungouz M, Blocklet D, et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother2006;55:469-74
   PubMed Web of Science ®Google Scholar
• Calzascia T, Masson F, Di Berardino-Besson W, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity2005;22:175-84
   PubMed Web of Science ®Google Scholar
• Prins RM, Shu CJ, Radu CG, et al. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother2008;57:1279-89
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res2005;11:4160-7
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Van Calenbergh F, Demaerel P, et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. J Neurosurg2004;100:492-7
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res2008;14:3098-104
   PubMed Web of Science ®Google Scholar
• Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res2005;11:5515-25
   PubMed Web of Science ®Google Scholar
• Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer2004;91:1656-62
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother2004;27:452-9
   PubMed Web of Science ®Google Scholar
• Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res2000;6:2209-18
   PubMed Web of Science ®Google Scholar
• Okada H, Lieberman FS, Edington HD, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neuro-Oncol2003;64:13-20
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Black KL, Liu G, et al. Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol2003;171:4927-33
   PubMed Web of Science ®Google Scholar
• Northwest Biotherapeutics DCVaxr-Brain Phase II Clinical Trial. Available from: http://www.nwbio.com/clinical_dcvax_brain.php [last accessed 13 November].
   Google Scholar
• Jager E, Ringhoffer M, Karbach J, et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer1996;66:470-6
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Das A, Liu G, et al. Clinical responsiveness of glioblastoma multiform to chemotherapy after vaccination. Clin Cancer Res2004;10:5316-26
   PubMed Web of Science ®Google Scholar
• Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer2003;3:666-75
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science2002;298:850-4
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastic melanoma. J Clin Oncol2005;23:2346-57
   PubMed Web of Science ®Google Scholar